{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:04:53Z","timestamp":1784678693865,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Canadian Institutes of Health Research"],"award-info":[{"award-number":["Canadian Institutes of Health Research"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","award":["Muscular Dystrophy Canada"],"award-info":[{"award-number":["Muscular Dystrophy Canada"]}],"id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare diseases affect over 300\u00a0million people globally, yet clinical trial conduct in rare disease populations remains complex due to small patient numbers, geographic dispersion, heterogeneous phenotypes, and limited trial infrastructure. Neuromuscular diseases (NMDs) exemplify these challenges. Coordinated trial networks have emerged as a strategy to improve feasibility, access, and trial performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Guided by the Consolidated Framework for Implementation Research (CFIR), we conducted a multi-phase qualitative needs assessment involving neuromuscular investigators and clinical trial personnel across Canada (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934) and clinical trial personnel (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) across Canada. Data were analyzed using conventional qualitative content analysis to identify barriers, facilitators, and capacity-building needs informing the early implementation of a Canadian Neuromuscular Clinical Trial Network (CTN).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key barriers included burdensome feasibility processes, limited workforce capacity, lack of centralized trial visibility, and fragmented coordination across stakeholders. Trial personnel highlighted unmet needs in disease-specific training, mentorship, peer networking, and workforce sustainability. Early Neuromuscular CTN strategies, including centralized feasibility triage, a national Community of Practice, one-on-one operational monitoring, mentorship, and alignment with patient and registry infrastructures directly addressed these challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Neuromuscular CTN describes a pragmatic and potentially transferable model for strengthening rare disease clinical trial ecosystems. By ensuring trials not only occur but are optimally supported and performed, coordinated networks can enhance trial readiness, equity of access, and long-term sustainability in rare disease research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04393-4","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:14:19Z","timestamp":1779786859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of a neuromuscular clinical trial network: a rare disease model for enhancing clinical trial readiness, capacity, and access in Canada"],"prefix":"10.1186","volume":"21","author":[{"given":"Kerri Lynn","family":"Schellenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4225-9075","authenticated-orcid":false,"given":"Homira","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Masnata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Stosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Lintern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochmuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"4393_CR1","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(24)00134-7","volume":"12","author":"G Baynam","year":"2024","unstructured":"Baynam G, Hartman AL, Letinturier MCV, et al. Global health for rare diseases through primary care. Lancet Glob Health. 2024;12:e1192\u20139. https:\/\/doi.org\/10.1016\/S2214-109X(24)00134-7.","journal-title":"Lancet Glob Health"},{"key":"4393_CR2","doi-asserted-by":"publisher","unstructured":"Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis 2023;18. https:\/\/doi.org\/10.1186\/s13023-023-02790-7","DOI":"10.1186\/s13023-023-02790-7"},{"key":"4393_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A. 2018;176:773\u201383. https:\/\/doi.org\/10.1002\/ajmg.a.38413.","journal-title":"Am J Med Genet A"},{"key":"4393_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13023-020-01624-0","volume":"16","author":"K Tingley","year":"2021","unstructured":"Tingley K, Coyle D, Graham ID, et al. Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research. Orphanet J Rare Dis. 2021;16:26. https:\/\/doi.org\/10.1186\/s13023-020-01624-0.","journal-title":"Orphanet J Rare Dis"},{"key":"4393_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41431-024-01604-z","volume":"32","author":"F Faye","year":"2024","unstructured":"Faye F, Crocione C, Anido de Pe\u00f1a R, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey. Eur J Hum Genet. 2024;32:1116\u201326. https:\/\/doi.org\/10.1038\/s41431-024-01604-z.","journal-title":"Eur J Hum Genet"},{"key":"4393_CR6","doi-asserted-by":"publisher","unstructured":"Cho A. Neuromuscular diseases: genomics-driven advances. Genomics Inf. 2024;22. https:\/\/doi.org\/10.1186\/S44342-024-00027-Y.","DOI":"10.1186\/S44342-024-00027-Y"},{"key":"4393_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1055\/a-2463-3385","volume":"46","author":"L Davalos","year":"2025","unstructured":"Davalos L, Kushlaf H. Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders. Semin Respir Crit Care Med. 2025;46:250\u20138. https:\/\/doi.org\/10.1055\/a-2463-3385.","journal-title":"Semin Respir Crit Care Med"},{"key":"4393_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/S41669-019-0161-0","volume":"4","author":"DT Tran","year":"2020","unstructured":"Tran DT, Akpinar I, Jacobs P. The Costs of Industry-Sponsored Drug Trials in Canada. Pharmacoecon Open. 2020;4:353\u20139. https:\/\/doi.org\/10.1007\/S41669-019-0161-0.","journal-title":"Pharmacoecon Open"},{"key":"4393_CR9","unstructured":"Clinical Research Regulation For Canada | ClinRegs. n.d. https:\/\/clinregs.niaid.nih.gov\/country\/canada#documentation_requirements"},{"key":"4393_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JND-200538","volume":"8","author":"V Hodgkinson","year":"2021","unstructured":"Hodgkinson V, Lounsberry J, M\u2019dahoma S, et al. The Canadian Neuromuscular Disease: A Decade of Facilitating Clinical Research Through a Nationwide, Pan-Neuromuscular Disease Registry the Creative Commons Attribution-Non Commercial License (CC BY-NC 4.0). J Neuromuscul Dis. 2021;8:53\u201361. https:\/\/doi.org\/10.3233\/JND-200538.","journal-title":"J Neuromuscul Dis"},{"key":"4393_CR11","doi-asserted-by":"publisher","unstructured":"Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4. https:\/\/doi.org\/10.1186\/1748-5908-4-50.","DOI":"10.1186\/1748-5908-4-50"},{"key":"4393_CR12","doi-asserted-by":"publisher","unstructured":"Skolarus TA, Lehmann T, Tabak RG, et al. Assessing citation networks for dissemination and implementation research frameworks. Implement Sci. 2017;12. https:\/\/doi.org\/10.1186\/s13012-017-0628-2.","DOI":"10.1186\/s13012-017-0628-2"},{"key":"4393_CR13","doi-asserted-by":"publisher","unstructured":"Reardon CM, Damschroder LJ, Ashcraft LE, et al. The Consolidated Framework for Implementation Research (CFIR) User guide: a five-step guide for conducting implementation research using the framework. Implement Sci. 2025;20. https:\/\/doi.org\/10.1186\/s13012-025-01450-7.","DOI":"10.1186\/s13012-025-01450-7"},{"key":"4393_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/17407745231177885","volume":"20","author":"SA Freel","year":"2023","unstructured":"Freel SA, Snyder DC, Bastarache K, et al. Now is the time to fix the clinical research workforce crisis. Clin Trials. 2023;20:457. https:\/\/doi.org\/10.1177\/17407745231177885.","journal-title":"Clin Trials"},{"key":"4393_CR15","unstructured":"Introduction to communities of practice \u2013 wenger-trayner. n.d. https:\/\/www.wenger-trayner.com\/introduction-to-communities-of-practice\/"},{"key":"4393_CR16","doi-asserted-by":"publisher","unstructured":"Rodger S, Lochm\u00fcller H, Tassoni A, et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8. https:\/\/doi.org\/10.1186\/1750-1172-8-171.","DOI":"10.1186\/1750-1172-8-171"},{"key":"4393_CR17","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/humu.22390","volume":"34","author":"CL Bladen","year":"2013","unstructured":"Bladen CL, Rafferty K, Straub V, et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013;34:1449\u201357. https:\/\/doi.org\/10.1002\/humu.22390.","journal-title":"Hum Mutat"},{"key":"4393_CR18","doi-asserted-by":"publisher","unstructured":"Atalaia A, Wandrei D, Lalout N, et al. EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. Orphanet J Rare Dis. 2024;19. https:\/\/doi.org\/10.1186\/s13023-024-03059-3.","DOI":"10.1186\/s13023-024-03059-3"},{"key":"4393_CR19","doi-asserted-by":"publisher","unstructured":"Lumsden JM, Urv TK. The Rare Diseases Clinical Research Network: a model for clinical trial readiness. Therapeutic Adv Rare Disease. 2023;4. https:\/\/doi.org\/10.1177\/26330040231219272.","DOI":"10.1177\/26330040231219272"},{"key":"4393_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4155\/cli.13.112","volume":"3","author":"L Zinman","year":"2013","unstructured":"Zinman L, Genge A, Figlewicz DA. Developing a consortium for ALS clinical research: the Canadian ALS Research Network. Clin Investig (Lond). 2013;3:1113\u20137. https:\/\/doi.org\/10.4155\/cli.13.112.","journal-title":"Clin Investig (Lond)"},{"key":"4393_CR21","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1017\/cts.2022.411","volume":"6","author":"JM Knapke","year":"2022","unstructured":"Knapke JM, Snyder DC, Carter K, et al. Issues for recruitment and retention of clinical research professionals at academic medical centers: Part 1 \u2013 collaborative conversations Un-Meeting findings. J Clin Transl Sci. 2022;6:e80. https:\/\/doi.org\/10.1017\/cts.2022.411.","journal-title":"J Clin Transl Sci"},{"key":"4393_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40120-022-00360-w","volume":"11","author":"IS Peterson","year":"2022","unstructured":"Peterson IS, Mazzella AJ, Belter LT, et al. The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices. Neurol Ther. 2022;11:1167\u201381. https:\/\/doi.org\/10.1007\/s40120-022-00360-w.","journal-title":"Neurol Ther"},{"key":"4393_CR23","doi-asserted-by":"publisher","first-page":"e70529","DOI":"10.1111\/hex.70529","volume":"28","author":"H Osman","year":"2025","unstructured":"Osman H, Adamji Z, Lintern S, et al. Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives. Health Expect. 2025;28:e70529. https:\/\/doi.org\/10.1111\/hex.70529.","journal-title":"Health Expect"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04393-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04393-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:44:09Z","timestamp":1784677449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04393-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4393"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04393-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"252"}}